Want to see HK:0767 full AI Analyst Report?
Top Page
Zhong Ji Longevity Science Group Limited
(0767)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$0.48
▼(-5.29% Downside)
Action:Reiterated
Date:08/26/26
The score is held back primarily by weak financial performance—ongoing net losses, compressed margins, and negative operating/free cash flow in 2024–2025—despite the support of a conservatively levered balance sheet. Technicals are a modest positive with the price above major moving averages and neutral momentum, while valuation remains challenged due to negative earnings and no indicated dividend yield.
Positive Factors
Conservative Balance Sheet
Very low leverage limits refinancing pressure and preserves financial flexibility. This gives the company a stronger base to absorb operating volatility and fund a potential turnaround.
Negative Factors
Persistent Net Losses
Persistent losses weaken retained capital and indicate that the current business model is not converting revenue into sustainable earnings. A prolonged loss period could constrain investment and require operational restructuring.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage limits refinancing pressure and preserves financial flexibility. This gives the company a stronger base to absorb operating volatility and fund a potential turnaround.
Read all positive factors
Zhong Ji Longevity Science Group Limited (0767) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$305.59M
Dividend YieldN/A
Average Volume (3M)2.88M
Price to Earnings (P/E)―
Beta (1Y)<0.01
Revenue Growth9.93%
EPS Growth80.14%
CountryHK
Employees43
SectorHealthcare
Sector Strength45
IndustryFinancial - Credit Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding636,654,300
10 Day Avg. Volume4,160,905
30 Day Avg. Volume2,880,860
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)0.75
Price to Sales (P/S)1.80
P/FCF Ratio-12.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhong Ji Longevity Science Group Limited Business Overview & Revenue Model
Company Description
Zhong Ji Longevity Science Group Limited operates as an investment holding entity, engaging in a broad spectrum of commercial endeavors. Its operations include providing money lending solutions across Hong Kong and Mainland China. The company's he...
Zhong Ji Longevity Science Group Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 165.18M | 168.63M | 64.99M | 89.44M | 62.98M |
| Gross Profit | 16.74M | 57.41M | 56.28M | 79.41M | 49.40M |
| EBITDA | -7.37M | -23.10M | 13.02M | 15.99M | 16.13M |
| Net Income | -16.75M | -34.73M | 2.31M | -904.00K | 6.05M |
Balance Sheet | |||||
| Total Assets | 499.91M | 525.63M | 509.25M | 484.84M | 517.50M |
| Cash, Cash Equivalents and Short-Term Investments | 24.30M | 47.84M | 81.08M | 60.07M | 19.44M |
| Total Debt | 5.57M | 19.11M | 20.20M | 11.76M | 12.93M |
| Total Liabilities | 74.92M | 125.49M | 78.79M | 63.99M | 46.78M |
| Stockholders Equity | 397.56M | 373.42M | 403.40M | 393.83M | 443.75M |
Cash Flow | |||||
| Free Cash Flow | -23.13M | -61.76M | 15.28M | 11.08M | -40.51M |
| Operating Cash Flow | -23.12M | -61.05M | 15.28M | 12.11M | -39.62M |
| Investing Cash Flow | -23.03M | 11.47M | 382.00K | 16.59M | 2.91M |
| Financing Cash Flow | 24.70M | 15.17M | 6.02M | -7.45M | 3.44M |
Zhong Ji Longevity Science Group Limited Technical Analysis
Positive
0.51
Price Trends
0.44
Positive
0.44
Positive
0.47
Positive
Market Momentum
0.02
Negative
53.96
Neutral
36.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0767, the sentiment is Positive. The current price of 0.51 is above the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.44, and above the 200-day MA of 0.47, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 53.96 is Neutral, neither overbought nor oversold. The STOCH value of 36.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0767.
Zhong Ji Longevity Science Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$24.93M | 0.94 | 8.19% | ― | 4.25% | 182.18% | |
55 Neutral | HK$229.50M | 12.23 | 2.74% | 4.30% | 74.12% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$305.59M | -30.97 | -2.65% | ― | 9.93% | 80.14% | |
45 Neutral | HK$62.84M | -0.74 | -17.33% | ― | 18.55% | -5.24% | |
44 Neutral | HK$1.20B | -120.63 | -3.17% | ― | -13.23% | 87.30% | |
40 Underperform | HK$95.98M | -4.00 | -2.60% | 1.75% | -27.42% | 78.84% |
* Healthcare Sector Average
HK:0767
Zhong Ji Longevity Science Group Limited
0.48
-0.13
-21.31%
HK:1660
Zhaobangji Properties Holdings Limited
0.20
0.07
61.16%
HK:0736
China Properties Investment Holdings Limited
0.19
-0.22
-54.63%
HK:8019
Hao Wen Holdings Ltd.
0.07
-0.31
-81.05%
HK:8223
Ziyuanyuan Holdings Group Ltd.
0.18
-1.10
-86.09%
HK:8525
Baiying Holdings Group Ltd.
0.85
0.00
0.00%
Zhong Ji Longevity Science Group Limited Corporate Events
Zhong Ji Longevity Science Group Delays Circular on Cell Lab Stake Acquisition
Aug 21, 2026
Zhong Ji Longevity Science Group Limited has announced a further delay in sending a shareholder circular related to its proposed major and connected transaction to acquire 25% of Asian Integrated Cell Laboratory Limited via the issuance of convert...
Zhong Ji Longevity Science Tightens Terms on Cell Lab Stake Acquisition
Aug 21, 2026
Zhong Ji Longevity Science Group Limited has updated the terms of its major and connected transaction to acquire 25% of Asian Integrated Cell Laboratory Limited, a deal to be settled through the issue of convertible notes under a specific mandate....
Zhong Ji Longevity Science Schedules Board Meeting to Approve Interim Results and Potential Dividend
Aug 17, 2026
Zhong Ji Longevity Science Group Limited has scheduled a board meeting for 27 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the potential declaration of an interim dividen...
Zhong Ji Longevity Science Group to Launch RMB1 Billion Health-Focused M&A Fund
Jul 7, 2026
Zhong Ji Longevity Science Group’s Shenzhen-based subsidiary Zhong Ji Health has signed a memorandum of cooperation with Shenzhen Zhongtou Huijin Fund Management to jointly set up a specialized mergers and acquisitions fund targeting the big...
Zhong Ji Longevity Science Group Clarifies Investment Strategy and Oversight in 2025 Report
Jul 2, 2026
Zhong Ji Longevity Science Group Limited has issued a supplemental announcement to its 2025 annual report detailing its cash and working capital management strategy and governance for significant investments. The company has established a Risk Man...
Zhong Ji Longevity Science Group Wins Full Shareholder Backing at AGM
Jun 30, 2026
Zhong Ji Longevity Science Group Limited, a Bermuda-incorporated company listed in Hong Kong under stock code 767, operates in the longevity science sector and is subject to Hong Kong’s listing and corporate governance rules. Its board struc...
Zhong Ji Longevity Science Delays Circular on Asian Cell Lab Acquisition
Jun 10, 2026
Zhong Ji Longevity Science Group Limited is a Bermuda-incorporated company listed in Hong Kong that focuses on longevity-related science and healthcare businesses. The group is pursuing strategic investments in advanced biomedical operations, incl...
Zhong Ji Longevity Science Group Sets 2026 AGM to Approve Accounts, Board and Share Mandate
Jun 8, 2026
Zhong Ji Longevity Science Group Limited has called its annual general meeting for 30 June 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements and directors’ and auditors’ reports for the yea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.